Overall, higher pCR rates were associated with HER2+ containing breast cancers (p = 0.003), being treated during time period 2 (p = 0.001) and using a nonanthracycline/taxane only regimen (e.g., carboplatin-containing or dual HER2 blockade) (p = 0.004). Here, ERBB2 is linked to breast cancer.